Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status: Recruiting
Location: See location...
Intervention Type: Genetic
Study Type: Observational
SUMMARY
It analyzes the Tumor microenvironment(TME) changes in non pathologic complete response(pCR) subjects among subjects who were administered neoadjuvant pembrolizumab and those who were not administered neoadjuvant pembrolizumab for triple negative breast cancer. (Neoadjuvant Weekly paclitaxel, Carboplatin +- Pembrolizumab followed by Doxorubicin, Cyclophosphamide +- Pembrolizumab regimen)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Triple negative breast cancer
• Subjects administered neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab or not
• Non pCR patients who are undergoing surgery after neoadjuvant chemotherapy
• Sign to informed consent
Locations
Other Locations
Republic of Korea
Samsung Medical Center
RECRUITING
Seoul
Contact Information
Primary
Yeon Hee Park, MD, Ph.D
yeonh.park@samsung.com
82-2-3410-1780
Time Frame
Start Date: 2023-03-02
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 50
Treatments
Subjects administered Neoadjuvant Pembrolizumab
Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide add Pembrolizumab
Subjects not administered Neoadjuvant Pembrolizumab
Neoadjuvant Weekly paclitaxel, Carboplatin followed by Doxorubicin, Cyclophosphamide
Related Therapeutic Areas
Sponsors
Leads: Samsung Medical Center